Hikma Pharmaceuticals PLC Cash Flow Conversion Efficiency
Hikma Pharmaceuticals PLC cash flow conversion efficiency. Based on the latest financial reports, Hikma Pharmaceuticals PLC (HIK) has a cash flow conversion efficiency ratio of 0.063x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX161.00 Million ≈ $19.59K USD) by net assets (GBX2.55 Billion ≈ $310.38K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Hikma Pharmaceuticals PLC (2002–2024)
Cash flow conversion efficiency of Hikma Pharmaceuticals PLC from 2002 to 2024. This chart illustrates how Hikma Pharmaceuticals PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Hikma Pharmaceuticals PLC for real-time trading data and today's change.
Hikma Pharmaceuticals PLC Cash Flow Conversion Ratio Explained
Hikma Pharmaceuticals PLC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Hikma Pharmaceuticals PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hikma Pharmaceuticals PLC ranked by their cash flow conversion efficiency. Also see Hikma Pharmaceuticals PLC (HIK) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vinyl Chemicals (India) Limited
NSE:VINYLINDIA
|
-0.462x |
|
Elite Naturel Organik Gida Sanayi ve Ticaret AS
IS:ELITE
|
-0.007x |
|
SensorView Co Ltd
KQ:321370
|
-0.080x |
|
NIGHTINGALE HEALTH EO 1
F:7XE
|
N/A |
|
ImageneBio, Inc.
NASDAQ:IMA
|
-0.064x |
|
Byuksan Corp
KO:007210
|
0.029x |
|
EITA Resources Bhd
KLSE:5208
|
0.038x |
|
Rightmove PLC
LSE:RMV
|
1.702x |
Annual Cash Flow Conversion Efficiency for Hikma Pharmaceuticals PLC (2002–2024)
The table below shows the annual cash flow conversion efficiency of Hikma Pharmaceuticals PLC from 2002 to 2024. Review HIK free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX2.32 Billion ≈ $282.40K |
GBX564.00 Million ≈ $68.62K |
0.243x | -11.71% |
| 2023-12-31 | GBX2.21 Billion ≈ $268.77K |
GBX608.00 Million ≈ $73.98K |
0.275x | +11.55% |
| 2022-12-31 | GBX2.15 Billion ≈ $261.35K |
GBX530.00 Million ≈ $64.49K |
0.247x | -4.59% |
| 2021-12-31 | GBX2.47 Billion ≈ $300.16K |
GBX638.00 Million ≈ $77.63K |
0.259x | +19.72% |
| 2020-12-31 | GBX2.15 Billion ≈ $261.35K |
GBX464.00 Million ≈ $56.46K |
0.216x | -2.56% |
| 2019-12-31 | GBX2.13 Billion ≈ $259.04K |
GBX472.00 Million ≈ $57.43K |
0.222x | -12.51% |
| 2018-12-31 | GBX1.70 Billion ≈ $206.48K |
GBX430.00 Million ≈ $52.32K |
0.253x | -12.60% |
| 2017-12-31 | GBX1.53 Billion ≈ $185.91K |
GBX443.00 Million ≈ $53.90K |
0.290x | +138.57% |
| 2016-12-31 | GBX2.41 Billion ≈ $293.35K |
GBX293.00 Million ≈ $35.65K |
0.122x | -55.11% |
| 2015-12-31 | GBX1.35 Billion ≈ $164.50K |
GBX366.00 Million ≈ $44.53K |
0.271x | -22.55% |
| 2014-12-31 | GBX1.22 Billion ≈ $147.95K |
GBX425.00 Million ≈ $51.71K |
0.350x | +7.24% |
| 2013-12-31 | GBX1.03 Billion ≈ $125.81K |
GBX337.00 Million ≈ $41.00K |
0.326x | +51.70% |
| 2012-12-31 | GBX847.85 Million ≈ $103.16K |
GBX182.16 Million ≈ $22.16K |
0.215x | +67.18% |
| 2011-12-31 | GBX798.63 Million ≈ $97.17K |
GBX102.64 Million ≈ $12.49K |
0.129x | -30.52% |
| 2010-12-31 | GBX750.30 Million ≈ $91.29K |
GBX138.79 Million ≈ $16.89K |
0.185x | +19.78% |
| 2009-12-31 | GBX683.26 Million ≈ $83.13K |
GBX105.52 Million ≈ $12.84K |
0.154x | +62.51% |
| 2008-12-31 | GBX609.00 Million ≈ $74.10K |
GBX57.87 Million ≈ $7.04K |
0.095x | -6.41% |
| 2007-12-31 | GBX424.66 Million ≈ $51.67K |
GBX43.12 Million ≈ $5.25K |
0.102x | +18.42% |
| 2006-12-31 | GBX349.80 Million ≈ $42.56K |
GBX29.99 Million ≈ $3.65K |
0.086x | -24.65% |
| 2005-12-31 | GBX287.48 Million ≈ $34.98K |
GBX32.71 Million ≈ $3.98K |
0.114x | -49.70% |
| 2004-12-31 | GBX145.18 Million ≈ $17.66K |
GBX32.84 Million ≈ $4.00K |
0.226x | -25.43% |
| 2003-12-31 | GBX60.47 Million ≈ $7.36K |
GBX18.35 Million ≈ $2.23K |
0.303x | +1.52% |
| 2002-12-31 | GBX48.03 Million ≈ $5.84K |
GBX14.35 Million ≈ $1.75K |
0.299x | -- |
About Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Generics segment offers oral, respiratory, and other generic and spe… Read more